AI Liquid Biopsy System EarlyDetect Achieves Stage-Zero Pancreatic Cancer Screening: 18-Month Early Warning

AI Liquid Biopsy System EarlyDetect Achieves Stage-Zero Pancreatic Cancer Screening

On February 13, 2028, Illumina subsidiary Grail published large-scale screening results in The Lancet Oncology. Its AI liquid biopsy system EarlyDetect identified 47 cases of stage-zero pancreatic cancer among 128,000 asymptomatic participants, approximately 18 months before traditional imaging diagnosis would typically detect the disease.

EarlyDetect detects early cancers by analyzing circulating tumor DNA (ctDNA) methylation patterns in blood. Grail's AI model, trained on data from over 300,000 cancer patients and healthy individuals, can simultaneously screen for more than 50 cancer types.

For pancreatic cancer screening specifically, EarlyDetect achieves 83% sensitivity and 99.5% specificity — meaning only 5 in 1,000 tested individuals would receive a false positive.

"Pancreatic cancer is called the silent killer because most patients are diagnosed at late stages," said Johns Hopkins pancreatic cancer center director Dr. Elizabeth Jaffee. "EarlyDetect gives us our first chance to catch this cancer at stage zero, when five-year survival exceeds 90%."

Grail plans to submit an expanded indication application to the FDA in Q3 2028 to include pancreatic cancer screening in its approved multi-cancer early detection product.